Spectrum Therapeutics, the medical division of Canopy Growth (TSX:WEED; NYSE:CGC) appointed Dr. Marcel Bonn-Miller as global clinical scientific director.
Canopy Growth (TSX:WEED; NYSE: CGC) acquired This Works in an all-cash transaction for £43 million. British-based This Works offers a range of high-quality natural skincare and sleep solution products, including deep...
Canopy Growth (TSX:WEED; NYSE:CGC) appointed Mike Lee as acting CFO, effective June 1, and subject to Health Canada security clearance required for all officers and directors of the company.
Canopy Growth (TSX:WEED; NYSE:CGC) unveiled Spectrum Therapeutics, a new global brand that will encompass all of the company’s ongoing commercial medical and clinical research operations. These include Spectrum...
Canopy Growth (TSX:WEED; NYSE:CGC) acquired C3 Cannabinoid Compound Co. for €225.9 million (CDN $342.9-million) in a transformative deal that furthers Canopy’s expansion in Europe with prescription medicines. The...
Canopy Growth (TSX:WEED; NYSE:CGC) secured a 308,000-square-foot facility on a 48-acre property in Kirkwood, NY for its hemp industrial park in the southern tier region of New York State. The vision for the property is...
Canopy Growth (TSX:WEED; NYSE:CGC) completed an all-cash acquisition of Spain-based licensed cannabis producer, Cáñamo y Fibras Naturales, (Cafina). The acquisition lays the foundation for Canopy to expand its European...
Canopy Growth (TSX:WEED) (NYSE:CGC) received a licence from New York State to process and produce hemp and will establish large-scale hemp extraction and product manufacturing in the state. Subject to board approval of...
Canopy Health Innovations, the research subsidiary of Canopy Growth (TSX:WEED; NYSE:CGC) that focuses on the development of therapeutic and natural health cannabis products, will get a big boost from a blockbuster $5...